Estrogen Receptor Beta – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)- Pipeline Review, H2 2019’, provides in depth analysis on Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Musculoskeletal Disorders, Women’s Health, Immunology, Male Health and Metabolic Disorders under development targeting Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)

– The report reviews Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Acadia Pharmaceuticals Inc

AstraZeneca Plc

Atossa Genetics Inc

Avivia BV

Eagle Pharmaceuticals Inc

Eli Lilly and Co

Endece LLC

EndoCeutics Inc

Helixmith Co Ltd

Huons Co Ltd

Karo Pharma AB

Kissei Pharmaceutical Co Ltd

MEI Pharma Inc

Oasmia Pharmaceutical AB”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Overview

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Companies Involved in Therapeutics Development

Acadia Pharmaceuticals Inc

AstraZeneca Plc

Atossa Genetics Inc

Avivia BV

Eagle Pharmaceuticals Inc

Eli Lilly and Co

Endece LLC

EndoCeutics Inc

Huons Global Co Ltd

Karo Pharma AB

Kissei Pharmaceutical Co Ltd

MEI Pharma Inc

Oasmia Pharmaceutical AB

ViroMed Co Ltd

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Drug Profiles

(bazedoxifene acetate + cholecalciferol) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AC-186 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene + GnRH Agonist + prasterone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene + prasterone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUS-131 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dehydrodiconiferyl alcohol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize ER-Beta for Multiple Sclerosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erteberel Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosfestrol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KB-3944 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KB-9520 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Libidua Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Loseasonique Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDC-1308 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDC-1352 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize ESR2 for Obesity and Depression Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Estrogen Beta Receptor for Inflammatory Diseases and Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-16234 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Dormant Products

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Discontinued Products

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Product Development Milestones

Featured News & Press Releases

Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston

Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product

Dec 11, 2017: AstraZeneca’s Faslodex Rejects for Use within NHS Scotland

Dec 07, 2017: Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant

Nov 15, 2017: Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib

Nov 14, 2017: Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib

Oct 13, 2017: Faslodex (Fulvestrant) Receives Positive CHMP Opinion For The Treatment Of Hormone Receptor-Positive Advanced Breast Cancer In Combination With Palbociclib

Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective

Aug 28, 2017: Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer

Jul 26, 2017: Faslodex receives EU approval as first-line therapy for advanced breast cancer

Jul 25, 2017: Atossa Genetics Provides Update on Fulvestrant Microcatheter Phase 2 Study

Jun 23, 2017: Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer

May 09, 2017: Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study

Feb 13, 2017: ENDECE Opens San Francisco Office

Jan 09, 2017: Atossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its Microcatheter

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Acadia Pharmaceuticals Inc, H2 2019

Pipeline by AstraZeneca Plc, H2 2019

Pipeline by Atossa Genetics Inc, H2 2019

Pipeline by Avivia BV, H2 2019

Pipeline by Eagle Pharmaceuticals Inc, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by Endece LLC, H2 2019

Pipeline by EndoCeutics Inc, H2 2019

Pipeline by Helixmith Co Ltd, H2 2019

Pipeline by Huons Co Ltd, H2 2019

Pipeline by Karo Pharma AB, H2 2019

Pipeline by Kissei Pharmaceutical Co Ltd, H2 2019

Pipeline by MEI Pharma Inc, H2 2019

Pipeline by Oasmia Pharmaceutical AB, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports